Diagnosis & Disease Information

Bryant Furlow

December 7, 2016

Extending adjuvant letrozole from 2.5 to 5 years does not improve disease-free survival or overall survival outcomes among women with breast cancer.

Bryant Furlow

December 7, 2016

Integration of newer targeted agents into combination therapies will necessitate the development of predictive biomarkers.

Bryant Furlow

December 7, 2016

Adding everolimus to fulvestrant improves progression-free survival (PFS) among postmenopausal women.

December 7, 2016

Many agents are in ongoing trials, and may provide additional options for patients with metastatic HER2-positive disease.

Leah Lawrence

December 6, 2016

Lack of research data and failure to consider patients’ functional age affects how older adults with breast cancer are managed.

Next post in SABCS 2016

Clinically Important Factors Identified for Trastuzumab Response in HER2-positive Patients